Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in ...
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 ...
The benefit of direct oral anticoagulants on stroke risk in patients with prior intracerebral hemorrhage and atrial ...
The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in P ...
Apixaban significantly reduces stroke risk in people with subclinical atrial fibrillation and prior stroke history.
In February 2024, Corewell Health introduced pulsed field ablation, a treatment procedure significantly safer than previous AFib treatments, at several of its Michigan hospitals. PFA applies a ...
14hon MSN
In patients with symptoms such as irregular heartbeats, dizziness, or fainting, or in individuals that physicians suspect may ...
Flossing was associated with a 44% lower risk of cardioembolic stroke, a 22% lower risk of ischemic stroke and a 12% lower risk of atrial fibrillation, according to research presented at the American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback